Source-grounded facts extracted from JOHNSON & JOHNSON's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
JOHNSON & JOHNSON reported first quarter ended March 29, 2026 results: revenue $24,062, net income $5,235, EPS $2.14.
“5,110 14.5 2.7 11.8 Western Hemisphere excluding U.S. 1,293 1,167 10.8 2.5 8.3 Asia-Pacific, Africa 3,591 3,311 8.5 6.1 2.4 International 10,732 9,588 11.9 3.9 8.0 Worldwide $24,062 21,893 9.9 % 6.4 3.5 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. Johnson & Johnson and subsidiaries”
D. Adamczyk departed as Director at JOHNSON & JOHNSON.
“D. Adamczyk notified the Company that he intends to retire from the Company’s Board of Directors in connection with an announcement on April 23 rd that he will join Goldman Sachs as a Partner.”
D. S. Davis retired as Director at JOHNSON & JOHNSON.
“On September 10, 2024, D. S. Davis retired as a Director of Johnson & Johnson after the successful transition of Audit Committee Chair responsibilities to D. Adamczyk.”
Peter M. Fasolo departed as Executive Vice President, Chief Human Resources Officer at JOHNSON & JOHNSON.
“On August 26, 2024, Johnson & Johnson (the Company) issued a press release announcing that Peter M. Fasolo, Executive Vice President, Chief Human Resources Officer (CHRO), has elected to retire.”
JOHNSON & JOHNSON reported first quarter ended March 31, 2024 results: revenue $21,383, net income $3,255, EPS $1.34.
“(Unaudited; in Millions Except Per Share Figures) FIRST QUARTER 2024 2023 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers $ 21,383 100.0 $ 20,894 100.0 2.3 Cost of products sold 6,511 30.4 6,687 32.0 (2.6) Gross Profit 14,872 69.6 14,207 68.0 4.7 Selling, marketing and administrative expenses 5,257 24.6 4,906”
JOHNSON & JOHNSON: Amended and restated by-laws effective April 25, 2024, with updates to special meeting requests, shareholder meeting conduct, voting standard, advance notice and proxy access provisions, CEO President clarification, and indemnification provisions (effective 2024-04-25).
“On April 25, 2024, the Board of Directors (the “Board”) of Johnson & Johnson (the “Company”) approved and adopted amended and restated by-laws of the Company (the “Amended and Restated By-Laws”), effective as of such date.”
JOHNSON & JOHNSON shareholders rejected Shareholder Proposal - gender-based compensation gaps and associated risks at the 2024-04-25 meeting.
“4. Shareholder Proposal - gender-based compensation gaps and associated risks: For Against Abstained Non-Votes 64,871,020.00 1,595,866,856.00 19,184,907.00 338,170,891.00”
JOHNSON & JOHNSON shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for 2024 at the 2024-04-25 meeting.
“3. Ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for 2024 : For Against Abstained Non-Votes 1,896,186,129.00 117,320,388.00 4,587,157.00 0”
JOHNSON & JOHNSON shareholders approved Advisory vote to approve named executive officer compensation (Say on Pay) at the 2024-04-25 meeting.
“2. Advisory vote to approve named executive officer compensation (Say on Pay): For Against Abstained Non-Votes 1,511,199,544.00 159,356,373.00 9,366,866.00 338,170,891.00”
JOHNSON & JOHNSON shareholders approved Election of Directors at the 2024-04-25 meeting.
“1. Election of Directors: Shares For Shares Against Shares Abstain Non-Votes D. Adamczyk 1,656,623,584 18,925,478 4,373,721 338,170,891 M. C. Beckerle 1,663,236,710 12,988,890 3,697,183 338,170,891 D. S. Davis 1,637,607,236 38,041,198 4,274,349 338,170,891 J. A. Doudna 1,663,406,168 12,832,643 3,683,972 338,170,891 J. Duato 1,561,512,061 109,541,207 8,869,515 338,170,891 M. A. Hewson 1,631,542,950 44,419,702 3,960,131 338,170,891 P. A. Johnson 1,662,656,052 13,581,894 3,684,837 338,170,891 H. Joly 1,656,506,211 19,141,858 4,274,714 338,170,891 M. B. McClellan 1,661,933,030 13,974,677 4,015,076 338,170,891 A. M. Mulcahy 1,624,143,536 52,044,434 3,734,813 338,170,891 M. A. Weinberger 1,651,183,425 24,483,916 4,255,442 338,170,891 N. Y. West 1,666,853,163 9,240,391 3,829,229 338,170,891 E. A. Woods 1,665,190,129 10,460,172 4,272,482 338,170,891”
JOHNSON & JOHNSON reported first quarter ended March 31, 2024 results: revenue $21,383 million, net income $5,354 million, EPS $2.20.
“On April 16, 2024, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the first quarter ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.